Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5461 to 5475 of 7681 results

  1. NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation test methods are performed. These studies should include the re-testing of stored non-small-cell lung cancer (NSCLC) tumour samples using different EGFR-TK mutation test methods and should link to patient outcomes.

    Recommendation ID DG9/1 Question NICE recommends that studies directly comparing different epidermal growth factor receptor tyrosine kinase

    Research recommendation
    Published
    9 June 2015

  2. NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular oedema should be conducted.

    Recommendation ID TA274/1 Question NICE recommends that further research directly comparing the clinical and cost effectiveness of ranibizumab

    Research recommendation
    Published
    9 June 2015

  3. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Recommendation ID TA254/1 Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related

    Research recommendation
    Published
    9 June 2015

  4. NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital episode, with a view to informing the cost-effectiveness modelling and reducing uncertainty.

    Recommendation ID DG13/4 Question NICE recommends that future trials should include longer-term follow-up, beyond the initial hospital

    Research recommendation
    Published
    9 June 2015

  5. NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the following arrangements are in place: - coordination of eculizumab use through an expert centre - monitoring systems to record the number of people with a diagnosis of atypical - haemolytic uraemic syndrome and the number who have eculizumab, and the dose and duration of treatment - a national protocol for starting and stopping eculizumab for clinical reasons - a research programme with robust methods to evaluate when stopping treatment or dose adjustment might occur.

    Recommendation ID HST1/1 Question NICE recommends the use of eculizumab for atypical haemolytic uraemic syndrome (aHUS) only if all the

    Research recommendation
    Published
    9 June 2015

  6. NICE recommends that health economic models are developed to capture the impact of interventions on short-term outcomes such as hypoglycaemia. In addition, the feasibility of incorporating more recently developed risk prediction models for cardiovascular disease such as QRisk2 and observational data from registries such as the Swedish National Diabetes Register into health economic models for type 1 diabetes should be explored.

    Recommendation ID DG21/3 Question NICE recommends that health economic models are developed to capture the impact of interventions on short-term

    Research recommendation
    Published
    11 April 2016

  7. NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.

    Recommendation ID TA316/1 Question NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide

    Research recommendation
    Published
    9 June 2015

  8. NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice.

    Recommendation ID TA293/1 Question NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin

    Research recommendation
    Published
    9 June 2015

  9. Noisy respiratory secretions:- In people considered to be in the last few hours and days of life, are antisecretory anti-muscarinic drugs (used alongside nursing interventions, such as repositioning and oropharyngeal suction) better at reducing noisy respiratory secretions and patient, family and carer distress without causing unwanted side effects, than nursing interventions alone?

    Recommendation ID NG31/3 Question Noisy respiratory secretions:- In people considered to be in the last few hours and days of life, are

    Research recommendation
    Published
    27 January 2016

  10. NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic dose adjustment of continuous infusion 5-FU in people with colorectal cancer.

    Recommendation ID DG16/2 Question NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic

    Research recommendation
    Published
    9 June 2015

  11. Non-invasive tests for diagnosing NAFLD and advanced liver fibrosis in children and young people:- Which non-invasive tests most accurately diagnose NAFLD and advanced liver fibrosis in children and young people?

    Recommendation ID NG49/3 Question Non-invasive tests for diagnosing NAFLD and advanced liver fibrosis in children and young people:- Which

    Research recommendation
    Published
    24 August 2016

  12. Non-invasive tests for diagnosing NAFLD in adults:- Which non-invasive tests are most accurate and cost-effective in identifying non-alcoholic fatty liver disease (NAFLD) in adults with risk factors, type 2 diabetes and metabolic syndrome?

    Recommendation ID NG49/1 Question Non-invasive tests for diagnosing NAFLD in adults:- Which non-invasive tests are most accurate and cost-effective

    Research recommendation
    Published
    24 August 2016

  13. Serological testing in people who test negative for anti-transglutaminase:- What is the sensitivity and specificity of IgA EMA and IgA DGP tests in detecting coeliac disease inpeople who test negative for IgA tTG?

    Recommendation ID NG20/2 Question Serological testing in people who test negative for anti-transglutaminase:- What is the sensitivity and

    Research recommendation
    Published
    13 October 2015

  14. Service delivery models:- Which models of service delivery are effective and cost-effective for older people with social care needs and multiple long-term conditions?

    Recommendation ID NG22/2 Question Service delivery models:- Which models of service delivery are effective and cost-effective for older

    Research recommendation
    Published
    11 December 2015

  15. Service provision for neutropenic sepsis in patients with cancer:- A prospective national cohort study should be carried out to assess the incidence of suspected and proven neutropenic sepsis in patients having anticancer treatment.

    Recommendation ID CG151/1 Question Service provision for neutropenic sepsis in patients with cancer:- A prospective national cohort study

    Research recommendation
    Published
    9 June 2015